Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

Notice Number: NOT-OD-20-084

Key Dates
Release Date: March 26, 2020
First Available Due Date: September 05, 2020
Expiration Date: January 06, 2022

Related Announcements

Issued by
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)


The Office of Research Infrastructure Programs (ORIP) is issuing this Notice to highlight its interest in receiving grant applications through Funding Opportunity Announcement PAR-20-098 (entitled “Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)”). ORIP will support applications that address technologies to deliver genome (or RNA) editors to animal cells, tissues, or organs in vivo. Use of animal models for the study of human diseases that are represented at ORIP supported centers is encouraged.

Application and Submission Information

This notice applies to due dates on or after September 5, 2020 and subsequent receipt dates through January 6, 2022.

Submit applications for this initiative using the following funding opportunity announcements (FOA) or any reissues of the announcement through the expiration date of this notice.

  • PAR-20-098 Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, all applicants should indicate that the submissions are in response to NOT-OD-20-084 in the Agency Routing Identifier field (Box 4.b) of the SF424 (R&R) Form. Applications without this information in box 4B will not be considered for this initiative.

Although ORIP is not listed as a Participating Organization in all the FOAs listed above, applications for this initiative will be accepted.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.


Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Miguel Contreras, Ph.D.
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-594-9410